Table 8.
TLR8 targeting ligands in clinical trials
| Ligand | Phase | Application | Target TLR adjuvant/drug | Sponsor/collaborators | NCT number | Type | Purpose/mechanism |
|---|---|---|---|---|---|---|---|
| VTX‐2337 (Motolimod) | Phase 1 | A variety and different stages of metastatic squamous neck cancer with occult primary squamous cell carcinoma | TLR8 agonist/adjuvant | University of Washington, NCI | NCT01334177 | SM | Immune stimulation |
| VTX‐2337 | Phase 1 | For various types and stages of colorectal, pancreatic, breast, melanoma, non‐small cell lung carcinoma, pancreatic, renal cell carcinoma and solid neoplasm | TLR8 agonist/adjuvant | Mayo Clinic, NCI | NCT02650635 | SM | Immune stimulation |
| VTX‐2337 | Phase 1 | Various types of ovarian cancers and fallopian tube carcinoma, recurrent ovarian carcinoma | TLR8 agonist/adjuvant | Gynecologic Oncology Group, NCI | NCT01294293 | SM | Immune stimulation |
| VTX‐2337 | Phase 2 | Epithelial ovarian cancer, fallopian tube cancer, primary peritoneal cancer | TLR8 agonist/adjuvant | VentiRx Pharmaceuticals Inc, Gynecologic Oncology Group | NCT01666444 | SM | Immune stimulation |
| VTX‐2337 (with radiotherapy) | Phases 1 and 2 | Low grade B‐Cell lymphoma | TLR8 agonist/adjuvant | VentiRx Pharmaceuticals Inc, Stanford University | NCT01289210 | SM | Immune stimulation |
| VTX‐2337 | Phase 2 | Carcinoma, squamous cell of head and neck | TLR8 agonist/adjuvant | VentiRx Pharmaceuticals Inc | NCT01836029 | SM | Immune stimulation |
| VTX‐2337 (with anti‐PD‐L1 antibody MEDI4736) | Phases 1 and 2 | Ovarian cancer | TLR8 agonist/adjuvant | Ludwig Institute for Cancer Research, MedImmune LLC, VentiRx Pharmaceuticals Inc, CRI New York City | NCT02431559 | SM | Immune stimulation |
Abbreviations: CRI, Cancer Research Institute; NCI, National Cancer Institute; NCT, national clinical trial; PD‐L1, programmed death‐ligand 1; SM, small molecule; TLR, Toll‐like recptor.